Genentech

Executive Summary

Genentech, a pioneer in biotechnology and a wholly owned member of the Roche Group, continues to drive innovation in serious diseases such as cancer, autoimmune disorders, and neurodegenerative conditions. With a rich history dating back to 1976, the company leverages deep expertise in antibodies, biologics, and small molecules to develop transformative therapies. Despite being privately held, Genentech's robust pipeline and strong financial backing from Roche position it as a leader in the biopharmaceutical industry. Its commitment to scientific excellence and addressing unmet medical needs underpins its sustained impact on global health.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on rozanolixizumab for myasthenia gravis70% success
• Q2 2026Phase 3 data readout for gantenerumab in Alzheimer's disease50% success
• Q4 2026Approval submission for mosunetuzumab in new indication60% success